MARKETS
PERPS
LIVE
79
SOCIAL
TRUST
RESEARCH
Cash
Browse
Live
79
Portfolio
Search
Social
Log in
Sign up
Trending
Elections
Politics
Sports
Culture
Crypto
Commodities
Climate
Economics
Mentions
Finance
Tech & Science
Browse
Live
79
Portfolio
Search
Social
Trending
Elections
Politics
Sports
Culture
Crypto
Commodities
Climate
Economics
Mentions
Finance
Tech & Science
All markets
2026 Mega IPOs
Companies
CEOs
IPOs
KPIs
M&A
Product launches
Industries
Healthcare
Technology
Markets
Foreign Exchange
Indices
Interest Rates
Match Ups
Industries
Trending
Frequency
Industries
Week 29: Price of NVIDIA’s RTX 5090 compute at end of week?
Above $0.50
1.44
x
68
%
Above $1.00
31.2
x
2
%
$31,146 vol
5 markets
Industries
Week 29: Price of NVIDIA’s B200 compute at end of week?
Above $6.50
1.73
x
46
%
Above $7.00
2.89
x
30
%
$24,494 vol
9 markets
Industries
NVIDIA B200 · Average hourly price in July
Above $6.00
1.42
x
32
%
Above $6.50
3.52
x
27
%
$21,861 vol
9 markets
Industries
Week 29: Price of NVIDIA’s A100 compute at end of week?
Above $1.00
1.60
x
61
%
Above $1.25
9.41
x
10
%
$5,427 vol
7 markets
Industries
Week 29: Price of NVIDIA’s H200 compute at end of week?
Above $4.00
1.50
x
53
%
Above $4.50
2.89
x
27
%
$13,877 vol
9 markets
Industries
NVIDIA H200 · Average hourly price in July
Above $4.50
2.66
x
36
%
Above $4.00
1.50
x
62
%
$39,589 vol
11 markets
Industries
NVIDIA RTX 5090 · Average hourly price in July
Above $0.50
1.50
x
69
%
Above $0.75
5.56
x
13
%
$9,684 vol
7 markets
Industries
Week 29: Price of NVIDIA’s H100 compute at end of week?
Above $2.50
1.93
x
47
%
Above $2.75
4.13
x
31
%
$3,602 vol
9 markets
Industries
NVIDIA A100 · Average hourly price in July
Above $1.00
2.29
x
41
%
Above $0.75
1.08
x
96
%
$9,573 vol
7 markets
Industries
NVIDIA H100 · Average hourly price in July
Above $2.50
1.67
x
57
%
Above $2.75
9.41
x
30
%
$438 vol
9 markets
Industries
FDA decision: Gedatolisib by Celcuity Inc. (July 2026)
Full Approval
1.19
x
83
%
Denied (CRL Issued)
9.41
x
10
%
$6,167 vol
5 markets
Industries
What will the price of TrendForce’s DDR5 be at year-end 2027?
Above $45.00
1.70
x
56
%
Above $55.00
2.24
x
39
%
$3,612 vol
9 markets
Industries
FDA decision: Zidesamtinib by Nuvalent (this year)
Yes
1.25
x
79
%
No
3.52
x
21
%
$50 vol
1 market
Industries
FDA decision: Venglustat by Sanofi (this year)
Yes
1.15
x
85
%
No
4.51
x
15
%
$0 vol
1 market
Industries
FDA decision: Saroglitazar by Zydus Therapeutics (this year)
Yes
1.31
x
71
%
No
2.98
x
29
%
$0 vol
1 market
Industries
FDA decision: Rusfertide by Protagonist Therapeutics (this year)
Yes
1.09
x
90
%
No
6.29
x
10
%
$64 vol
1 market
Industries
FDA decision: Ivonescimab by Summit Therapeutics (this year)
Yes
1.57
x
62
%
No
2.19
x
38
%
$115 vol
1 market
Industries
FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)
Yes
1.22
x
74
%
No
3.80
x
26
%
$30 vol
1 market
Industries
FDA decision: Iberdomide by Celgene (this year)
Yes
1.40
x
70
%
No
2.66
x
30
%
$13 vol
1 market
Industries
FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)
Yes
1.44
x
62
%
No
2.59
x
38
%
$90 vol
1 market
Industries
FDA decision: Brepocitinib by Priovant Therapeutics (this year)
Yes
1.22
x
74
%
No
3.80
x
26
%
$47 vol
1 market
Industries
FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)
Yes
1.05
x
95
%
No
9.41
x
5
%
$11 vol
1 market
Industries
FDA decision: Bepirovirsen by GlaxoSmithKline (this year)
Yes
1.29
x
76
%
No
3.18
x
24
%
$64 vol
1 market
Industries
FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)
Yes
1.06
x
89
%
No
8.56
x
11
%
$18 vol
1 market